Journal
LEUKEMIA RESEARCH
Volume 38, Issue 1, Pages 10-20Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.09.011
Keywords
BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations
Categories
Funding
- ARIAD Pharmaceuticals, Inc.
Ask authors/readers for more resources
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T3151 mutant has proven particularly difficult to target. This review summarizes the prevalence impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detect of mutatkins. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available